Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02722356
Other study ID # 417969-1
Secondary ID
Status Completed
Phase N/A
First received March 14, 2016
Last updated March 8, 2017
Start date April 2016
Est. completion date February 28, 2017

Study information

Verified date March 2017
Source C.R.Darnall Army Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The proposed study is a prospective, randomized, active control, open label study. One hundred sixty subjects undergoing elective cesarean section will be randomly assigned to one of two groups (n = 80 per group): the oxytocin protocol group or the standard practice group. The oxytocin protocol group will receive oxytocin boluses along with a regulated infusion according to a stepwise algorithm following delivery of the placenta. The standard practice group will receive oxytocin via a free flowing ("wide-open") infusion with a concentration of 30 IU per 500 mL of 0.9% normal saline following the delivery of the placenta. Primary outcomes include uterine tone (adequate or inadequate) as assessed by the surgeon, amount of time required to establish adequate uterine tone following the delivery of the infant, total dose of oxytocin required to establish adequate uterine tone, and total calculated blood loss based on pre-operative and post-operative hematocrit concentrations. Secondary outcomes include total estimated blood loss as agreed upon by the surgeon and the anesthesia provider, use of additional uterotonic drugs, mean arterial pressure, and incidence of oxytocin side effects (nausea, chest tightness/pain, and ST-segment changes).


Description:

The proposed study is a prospective, randomized, active control, open label between subjects design. One hundred sixty subjects will be randomly assigned to one of two groups (n = 80 per group): the oxytocin protocol group or the standard practice group. The following is a summary of the procedures used in this study:

1. All patients scheduled for an elective cesarean section will be prescreened by the investigator that is assigned as the student registered nurse anesthetist (SRNA) for that case. After obtaining informed consent and a HIPAA authorization, a full screening for eligibility will be conducted by the investigator. If determined eligible, subjects will be enrolled in the study and assigned a unique study code. Study codes will be assigned sequentially (001, 002, 003, etc.). Subjects will then be randomly allocated to one of the two groups with the use of a computer generated random number program.

2. Prior to the scheduled cesarean section investigators will record subject's age, height, weight, body mass index (BMI), parity, and gestational age. Baseline vital signs will be obtained before the start of anesthesia (blood pressure, mean arterial pressure, heart rate, respiratory rate, pulse oximetry, and temperature). A pre-operative complete blood count (CBC) will be drawn in order to obtain baseline hematocrit concentration. Procedures in this section are part of standard clinical care.

3. All subjects will have an 18-gauge IV catheter placed in the left and right upper extremity and Lactated Ringer's solution will be administered at the anesthesia provider's discretion. Standard monitors will be applied with blood pressure set to cycle at 3-minute intervals. Procedures in this section are part of standard clinical care.

4. Neuraxial anesthesia will be administered at the anesthesia provider's discretion based on patient assessment. A T4 sensory level will be established prior to beginning the cesarean section. Procedures in this section are part of standard clinical care.

5. Heart rate, ECG rhythm with ST-segment analysis, end-tidal carbon dioxide (CO2), temperature, and pulse oximetry will be monitored continuously throughout the procedure. Blood pressure and mean arterial pressure will be measured at three-minute intervals. A Foley catheter will be inserted and used to measure urine output. Procedures in this section are part of standard clinical care.

6. Throughout the procedure vasopressor drugs, crystalloids, and colloids will be administered at the anesthesia provider's discretion. Procedures in this section are part of standard clinical care.

7. Immediately after delivery of the placenta, oxytocin will be administered per the allocated group (see below). The surgeon will be blinded to the treatment group.

8. The surgeon will assess uterine tone at 3, 6, and 9 minutes following the first dose of oxytocin and deem it adequate or inadequate.

9. Subject complaints of nausea or chest tightness/pain at any time after the first dose of oxytocin will be recorded.

10. At the conclusion of the cesarean section, the amount of time required to establish adequate uterine tone following the delivery of the placenta and the total dose of oxytocin required to establish adequate uterine tone will be recorded.

11. Estimated blood loss as agreed upon by the surgeon and the anesthesia provider, need for additional uterotonic drugs, total fluid requirement (crystalloids, colloids, and blood products), total urine output, and surgical time will also be recorded at the conclusion of the procedure.

12. A post-operative CBC will be drawn 24 hours after the procedure and will be used to calculate blood loss based on the change from the pre-operative hematocrit concentration. Procedures in this section are part of standard clinical care.

13. Data will be recorded manually on a data collection sheet during the procedure and transferred to an electronic data spreadsheet. No identifying patient information will be used on data collection sheets or the electronic data spreadsheet; subjects will be identified by their unique study code.

14. Data collected will be statistically analyzed. Means, standard deviations, and covariances will be calculated for the groups. Patient characteristics such as age, weight, parity, prior cesarean section, gestational age, and baseline hematocrit will be analyzed using a multivariate analysis of variance (MANOVA) in order to determine if groups are equivalent on these parameters. An independent t-test will be used to analyze differences between the groups for continuous variables: time to adequate uterine tone, total oxytocin dose, estimated blood loss, and calculated blood loss. A Fisher's exact test will be used to analyze differences between the groups for categorical variables: uterine tone at 3, 6, and 9 minutes (adequate/inadequate), use of additional uterotonics, incidence of nausea, incidence of chest pain/tightness, and incidence of ST-segment changes. A repeated measures analysis of variance (ANOVA) with groups as the between-subjects factor and times as the within-subjects will be used to analyze differences between the groups relative to mean arterial pressure. If significance is detected, a post hoc comparison will be made using the Tukey honestly significant difference test.

Oxytocin Protocol Group Upon delivery of the placenta with confirmation from the surgeon, 3 international units (IU) of oxytocin will be administered via slow intravenous (IV) push over 30 seconds and an oxytocin infusion will be initiated at 3 IU per hour (50 mL/hr regulated by an IV pump). Investigators will wait three minutes to reassess uterine tone. If uterine tone is inadequate, an additional 3 IU bolus of oxytocin will be administered via slow IV push over 30 seconds and the oxytocin infusion will be increased to 6 IU per hour (100 mL/hr). Investigators will then wait an additional three minutes to reassess uterine tone. If uterine tone continues to be inadequate, another 3 IU bolus of oxytocin will be administered via slow IV push over 30 seconds and the oxytocin infusion will be increased to 9 IU per hour (150 mL/hr). The investigators will again wait an additional three minutes to reassess uterine tone. If uterine tone continues to be inadequate, an alternative uterotonic will be administered at the surgeon's discretion (methylergonovine 0.2 mg intramuscular [IM], carboprost tromethamine 0.25 mg IM or intramyometrial, or misoprostol 600 mcg buccal or 800-1000 mcg rectal). In the event the surgeon determines additional uterotonics are required prior to the third dose of oxytocin, the subject will be excluded from the study and additional uterotonics will be administered as necessary. Similarly, in the event the surgeon determines supplementary oxytocin is required and the protocol cannot be followed, the subject will be excluded from the study and additional oxytocin will be administered as necessary.

Standard Practice Group Upon delivery of the placenta, a free-flowing ("wide-open") oxytocin infusion will be initiated. The oxytocin infusion will be regulated at the anesthesia provider's discretion with a standard IV tubing roll-clamp and adjustments will be made as necessary after conferring with the surgeon. If adequate uterine tone is not achieved in a reasonable timeframe, the surgeon may request for an additional 20 units of oxytocin to be added to the infusion, thereby increasing the total dose of oxytocin in the 500 mL bag from 30 units to 50 units. Additional uterotonics may be requested at any time at the surgeon's discretion (methylergonovine 0.2 mg IM, carboprost tromethamine 0.25 mg IM or intramyometrial, or misoprostol 600 mcg buccal or 800-1000 mcg rectal).


Recruitment information / eligibility

Status Completed
Enrollment 64
Est. completion date February 28, 2017
Est. primary completion date February 28, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Pregnant women with American Society of Anesthesiologists (ASA) physical status II (subjects with ASA physical status III based solely on a body mass index [BMI] = 40 will be included in the study)

- Over 18 years of age

- Undergoing an elective cesarean section under neuraxial anesthesia

Exclusion Criteria:

- Maternal or obstetrician refusal

- Multiple gestation

- Ruptured membranes

- Abnormal placentation

- Preexisting coagulopathy

- Macrosomia

- Chorioamnionitis

- Diabetes mellitus (preexisting, not gestational)

- Uterine fibroids

- Contraindication to neuraxial anesthesia

- Previous allergic reaction to synthetic oxytocin

Study Design


Intervention

Drug:
Oxytocin
Oxytocin administered per oxytocin group or standard practice group (see above)

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
C.R.Darnall Army Medical Center

Outcome

Type Measure Description Time frame Safety issue
Primary Change in uterine tone Uterine tone deemed adequate or inadequate as assessed by the surgeon 3, 6, and 9 minutes after first dose of oxytocin
Primary Time to adequate uterine tone Amount of time (minutes) required to establish adequate uterine tone following the delivery of the infant From the delivery of the infant to the completion of the cesarean section
Primary Oxytocin dose Total dose of oxytocin required to establish adequate uterine tone Duration of cesarean section
Primary Total calculated blood loss Total calculated blood loss based on pre-operative and post-operative hematocrit concentrations 24 hours pre-op to 24 hours post-op
Secondary Total estimated blood loss Total estimated blood loss as agreed upon by the surgeon and the anesthesia provider Duration of cesarean section
Secondary Additional uterotonic drugs (in addition to oxytocin) required to establish adequate uterine tone: yes/no Duration of cesarean section
Secondary Oxytocin side effects incidence of oxytocin side effects (nausea, chest tightness/pain, and ST-segment changes) Duration of cesarean section
See also
  Status Clinical Trial Phase
Completed NCT03052699 - Medium and Long-term Complications of the Patients Having Had a Vaginal Caesarian in Hospital René Dubos N/A
Completed NCT01412073 - Control of Blood Loss During Caesarean Section Phase 3
Completed NCT01851187 - Effect of Perinatal Emotional Management on Maternal Emotion and Delivery Outcomes N/A
Completed NCT01890720 - Incisional Negative Pressure Wound Therapy for Prevention of Postoperative Infections Following Caesarean Section N/A
Completed NCT02542748 - Comparison of Norepinephrine and Ephedrine on Hypotension After Spinal Anesthesia in Parturients N/A
Enrolling by invitation NCT02694653 - Preoperative Cesarean Section Intravenous Acetaminophen and Postoperative Pain Control Phase 1
Completed NCT01723605 - Insitu Repair Versus Uterine Exeriorization During Cesarean Section Phase 3
Withdrawn NCT01516697 - Non-invasive Cardiac Output Monitoring in Obstetric Patients Phase 4
Completed NCT01741610 - Fluid Coloading and the Incidence of Hypotension Phase 4
Terminated NCT02838017 - Tissue Adhesive vs. Sterile Strips After Cesarean Delivery N/A
Completed NCT02587013 - Comparison of Uterine Repair Methods for Cesarean Delivery N/A
Terminated NCT02036697 - Hemodynamic Effects of Low Dose Spinal Anesthesia for Cesarean Section N/A
Recruiting NCT01954719 - Is Routine Cervical Dilatation Necessary During Elective Caesarean Section? A Randomised Controlled Trial N/A
Terminated NCT02799667 - Do Single Use Negative Pressure Dressings Reduce Wound Complications in Obese Women After Cesarean Delivery N/A
Completed NCT02459093 - Subcuticular Suture for Cesarean Skin Incision Closure Phase 4
Completed NCT01858467 - Supreme LMA and Endotracheal Intubation Use in Caesarean Section N/A
Completed NCT01891006 - Intervention for Postpartum Infections Following Caesarean Section N/A
Withdrawn NCT02893696 - Extra Sitting Time After Spinal Anesthesia for Cesarean Section and Fetal Well-being N/A
Completed NCT02785094 - Education and Social Media Versus Non-Indicated Caesarean Section Rate in Egypt N/A
Completed NCT02332278 - Early Oral Feeding Versus Traditional Postoperative Care After Cesarean Section. N/A